Bi-functional compounds and methods for targeted ubiquitination of androgen receptor
The present invention relates to bi-functional compounds which function to recruit endogenous proteins to an E3 ubiquitin ligase for degradation, and methods for using same. More specifically, the present disclosure provides specific proteolysis targeting chimera (PROTAC) molecules which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, in particular the androgen receptor of a slice variant of AR which lacks the LBD, labelled as AR-V7, which are then degraded and/or otherwise inhibited by the compounds as described herein.
1. A compound having a chemical structure:
ARB-Link-E3LB
wherein ARB is an AR binding moiety that does not bind to a ligand binding domain, E3LB is an E3 ligase binding moiety, and Link is a linker coupling the AR binding moiety to the E3 ligase binding moiety; and
wherein the E3LB moiety is a structure selected from the group consisting of:
wherein “ ” in the above structures, represents a bond that may be stereospecific ((R) or (S)), or non-stereospecific;
R 1 is each independently selected from H, OH, CONH 2 , CONR 2 R 3 , SONH 2 , SONR 2 R 3 , SO 2 NH 2 , SO 2 NR 2 R 3 , NHCOC 1-3 alkyl, NR 2 COC 1-3 alkyl, NR 2 SO 2 C 1-3 alkyl, NR 2 SOC 1-3 alkyl, CN, C≡CH, NH, NR 2 R 3 , OCH 3 , OC 1-3 alkyl, CHF 2 , CH 2 F, CF 3 , halo, and C 1-6 alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more halo or C 1-6 alkoxyl or, if applicable, taken together with an R on an adjacent bonded atom, together with the atoms they are attached to, form a 3-6 membered ring alicyclic, aryl, or heteroaryl system containing 0-2 heteroatoms;
R 2 and R 3 are independently H, halo, C 1-6 alkyl wherein said alkyl is optionally substituted by 1 or more F, or taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms;
R 4 is selected from the group consisting of H, alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more R 5 , OH, R 5 OCOOR 6 , R 5 OCONR 5 R 7 , CH 2 -heterocyclyl optionally substituted with R 5 , or benzyl optionally substituted with R 5 ;
R 5 and R 7 are each independently a bond, H, alkyl, cycloalkyl, aryl, hetaryl heterocyclyl, or —C(═O)R 6 , each of which is optionally substituted;
R 6 is selected from CONR 5 R 7 , OR 5 , NR 5 R 7 , SR 5 , SO 2 R 5 , SO 2 NR 5 R 7 , CR 5 R 7 , CR 5 NR 5 R 7 , aryl, hetaryl, alkyl wherein said alkyl is linear or branched and is optionally substituted, cycloalkyl, heterocyclyl, P(O)(OR 5 )R 7 , P(O)R 5 R 7 , OP(O)(OR 5 )R 7 , OP(O)R 5 R 7 , Cl, F, Br, I, CF 3 , CHF 2 , CH 2 F, CN, NR 5 SO 2 NR 5 R 7 , NR 5 CONR 5 R 7 , CONR 5 COR 7 , NR 5 C(═N—CN)NR 5 R 7 , C(═N—CN)NR 5 R 7 , NR 5 C(—N═CN)R 7 , NR 5 C(═C—NO 2 )NR 5 R 7 , SO 2 NR 5 COR 7 , NO 2 , CO 2 R 5 , C(C═N—OR 5 )R 7 , CR 5 , CR 5 R 7 , CCR 5 , S(C═O)(C═N—R 5 )R 7 , SF 5 , R 5 NR 5 R 7 , (R 5 O) n R 7 , or OCF 3 , where n is an integer from 1 to 10;
and wherein, the AR binding moiety is a structure selected from the group consisting of:
wherein:
Ring1 is 3-7 membered alicyclic with 0-4 heteroatoms and substituted by 1 or more halo, CN, C≡CH, C 1-6 alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more C 1-6 alkoxy, C 1-6 alkoxy wherein said alkoxy is linear or branched and is optionally substituted by 1 or more halo, C 2-6 alkenyl, or C 2-6 alkynyl, bridged or spiro, bicyclic rings with 0-4 heteroatoms and substituted by 1 or more halo, CN, C≡CH, C 1-6 alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more halo or C 1-6 alkoxy, C 1-6 alkoxy wherein said alkoxy is linear or branched and is optionally substituted by 1 or more halo, C 2-6 alkenyl, C 2-6 alkynyl, or
Ring2 is aryl, 2-benzyloxy-3,4-difluoro, heteroaryl independently substituted by 1 or more halo, hydroxyl, CN, C≡CH, NR 102 R 103 , OCH 3 , OC 1-3 alkyl wherein said alkyl is optionally substituted by 1 or more halo, C 1-6 alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more halo or C 1-6 alkoxy, C 1-6 alkoxy wherein said alkoxy is linear or branched and is optionally substituted by 1 or more halo, C 2-6 alkenyl, C 2-6 alkynyl, 3-6 membered alicyclic with 0-4 heteroatoms and substituted with 1 or more halo, hydroxyl, CN, C≡CH, C 1-6 alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more halo or C 1-6 alkoxy, C 1-6 alkoxy wherein said alkoxy is linear or branched and is optionally substituted by 1 or more halo or C 1-6 alkoxy C 2-6 alkenyl, or C 2-6 alkynyl, wherein R 102 and R 103 are independently H, halo, C 1-6 alkyl wherein said alkyl is optionally substituted by 1 or more F or, taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms,
and
R 101 is independently H, OH, CONH 2 , CONR 102 R 103 , SONH 2 , SONR 102 R 103 , SO 2 NH 2 , SO 2 NR 102 R 103 , NHCOC 1-3 alkyl wherein said alkyl is optionally substituted by 1 or more halo, NR 102 COC 1-3 alkyl wherein said alkyl is optionally substituted by 1 or more halo, NR 102 SO 2 C 1-3 alkyl wherein said alkyl is optionally substituted by 1 or more halo, NR 102 SO 2 C 1-3 alkyl wherein said alkyl is optionally substituted by 1 or more halo, CN, C≡CH, NH 2 , NR 102 R 103 , OCH 3 , OC 1-3 alkyl wherein said alkyl is optionally substituted by 1 or more halo, CHF 2 , CH 2 F, CF 3 , halo, C 1-6 alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more halo or C 1-6 alkoxy or, taken together with an R 101 on an adjacent bonded atom, together with the atoms they are attached to, form a 3-6 membered ring alicyclic, aryl, or heteroaryl system containing 0-2 heteroatoms, wherein R 102 and R 103 are independently H, halo, C 1-6 alkyl wherein said alkyl is optionally substituted by 1 or more F or, taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms.
2. The compound of claim 1 , wherein the AR binding moiety is a structure:
wherein:
Ring1 is 3-7 membered alicyclic with 0-4 heteroatoms and substituted by 1 or more halo, CN, C≡CH, C 1-6 alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more C 1-6 alkoxy, C 1-6 alkoxy wherein said alkoxy is linear or branched and is optionally substituted by 1 or more halo, C 2-6 alkenyl, or C 2-6 alkynyl, bridged or spiro, bicyclic rings with 0-4 heteroatoms and substituted by 1 or more halo, CN, C≡CH, C 1-6 alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more halo or C 1-6 alkoxy, C 1-6 alkoxy wherein said alkoxy is linear or branched and is optionally substituted by 1 or more halo, C 2-6 alkenyl, C 2-6 alkynyl, or
Ring2 is aryl, 2-benzyloxy-3,4-difluoro, heteroaryl independently substituted by 1 or more halo, hydroxyl, CN, C≡CH, NR 102 R 103 , OCH 3 , OC 1-3 alkyl wherein said alkyl is optionally substituted by 1 or more halo, C 1-6 alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more halo or C 1-6 alkoxy, C 1-6 alkoxy wherein said alkoxy is linear or branched and is optionally substituted by 1 or more halo, C 2-6 alkynyl, 3-6 membered alicyclic with 0-4 heteroatoms and substituted with 1 or more halo, hydroxyl, CN, C≡CH, C 1-6 alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more halo or C 1-6 alkoxy, C 1-6 alkoxy wherein said alkoxy is linear or branched and is optionally substituted by 1 or more halo or C 1-6 alkoxy, C 2-6 alkenyl, or C 2-6 alkynyl, wherein R 102 and R 103 are independently H, halo, C 1-6 alkyl wherein said alkyl is 1 optionally substituted by 1 or more F or, taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms,
and
R 101 is independently H, OH, CONH 2 , CONR 102 R 103 , SONH 2 , SONR 102 R 103 , SO 2 NH 2 , SO 2 NR 102 R 103 , NHCOC 1-3 alkyl wherein said alkyl is optionally substituted by 1 or more halo, NR 102 COC 1-3 alkyl wherein said alkyl is optionally substituted by 1 or more halo, NR 102 SO 2 C 1-3 alkyl wherein said alkyl is optionally substituted by 1 or more halo, NR 102 SO 2 C 1-3 alkyl wherein said alkyl is optionally substituted by 1 or more halo, CN, C≡CH, NH 2 , NR 102 R 103 , OCH 3 , OC 1-3 alkyl wherein said alkyl is optionally substituted by 1 or more halo, CHF 2 , CH 2 F, CF 3 , halo, C 1-6 alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more halo or C 1-6 alkoxy or, taken together with an R 101 on an adjacent bonded atom, together with the atoms they are attached to, form a 3-6 membered ring alicyclic, aryl, or heteroaryl system containing 0-2 heteroatoms, wherein R 102 and R 103 are independently H, halo, C 1-6 alkyl wherein said alkyl is optionally substituted by 1 or more F or, taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms.
3. The compound of claim 1 , wherein the linker comprises a chemical structure represented by -A q -, in which q is an integer greater than 1, and A is independently selected from the group consisting of a bond, CR L1 R L2 , O, S, SO, SO 2 , NR L3 , SO 2 NR L3 , SONR L3 , CONR L3 , NR L3 CONR L4 , NR L3 SO 2 NR L4 , CO, CR L1 ═CR L2 , C≡C, SiR L1 R L2 , P(O)R L1 , P(O)OR L1 , NR L3 C(═NCN)NR L4 , NR L3 C(═NCN), NR L3 C(═CNO 2 )NR L4 , C 3-11 cycloalkyl wherein said cycloalkyl is optionally substituted with 0-6 R L1 and/or R L2 groups, and heteroaryl wherein said heteroaryl is optionally substituted with 0-6 R L1 and/or R L2 groups, wherein R L1 , R L2 , R L3 , R L4 and R L5 are each independently selected from the group consisting of H, halo, C 1-8 alkyl, OC 1-8 alkyl, SC 1-8 alkyl, NHC 1-8 alkyl, N(C 1-8 alkyl) 2 , C 3-11 cycloalkyl, aryl, heteroaryl, C 3-11 heterocyclyl, OC 1-8 cycloalkyl, SC 1-8 cycloalkyl, NHC 1-8 cycloalkyl, N(C 1-8 cycloalkyl) 2 , N(C 1-8 cycloalkyl)(C 1-8 alkyl), OH, NH 2 , SH, SO 2 C 1-8 alkyl, P(O)(OC 1-8 alkyl)(C 1-8 alkyl), P(O)(OC 1-8 alkyl) 2 , CC—C 1-8 alkyl, CCH, CH═CH(C 1-8 alkyl), C(C 1-8 alkyl)═CH(C 1-8 alkyl), C(C 1-8 alkyl)═C(C 1-8 alkyl) 2 , Si(OH) 3 , SiC(i-s alkyl) 3 , Si(OH)(C 1-8 alkyl) 2 , COC 1-8 alkyl, CO 2 H, CN, CF 3 , CHF 2 , CH 2 F, NO 2 , SF 5 , SO 2 NHC 1-8 alkyl, SO 2 NHC 1-8 alkyl, SO 2 N(C 1-8 alkyl) 2 , SONHC 1-8 alkyl, SON(C 1-8 alkyl) 2 , CONHC 1-8 alkyl, CON(C 1-8 alkyl) 2 , N(C 1-8 alkyl)CONH(C 1-8 alkyl), N(C 1-8 alkyl)CON(C 1-8 alkyl) 2 , NHCONH(C 1-8 alkyl), NHCON(C 1-8 alkyl) 2 , NHCONH 2 , N(C 1-8 alkyl)SO 2 NH(C 1-8 alkyl), N(C 1-8 alkyl)SO 2 N(C 1-8 alkyl) 2 , NHSO 2 NH(C 1-8 alkyl), NHSO 2 N(C 1-8 alkyl) 2 and NHSO 2 NH 2 , and wherein R L1 and R L2 each, independently may be linked to another A group to form a cycloalkyl and or heterocyclyl moiety that can be further substituted with 0-4 R L5 groups.
4. The compound of claim 1 , wherein the linker comprises a structure selected from the group consisting of:
5. The compound according to claim 1 , wherein the compound is selected from the group consisting of:
2-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)-N-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)acetamide,
2-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)-N-(8-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)octyl)acetamide,
2-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)-N-(10-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)decyl)acetamide,
2-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)-N-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethyl)acetamide,
2-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)-N-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)acetamide,
2-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)-N-(14-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)-3,6,9,12-tetraoxatetradecyl)acetamide,
2-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)-N-(6-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)hexyl)acetamide,
2-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)-N-(8-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)octyl)acetamide,
2-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)-N-(10-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)decyl)acetamide,
2-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)-N-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamido)ethoxy)ethoxy)ethyl)acetamide,
2-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)-N-(1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-2-oxo-6,9,12-trioxa-3-azatetradecan-14-yl)acetamide,
4-((2-(2-(2-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione,
4-((2-(2-(2-(2-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)ethoxy)ethoxy)ethoxy)ethyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione,
N-(14-(2,3-difluoro-6-(2-morpholinothiazol-4-yl)phenoxy)-3,6,9,12-tetraoxatetradecyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide,
N-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-1-(2-morpholinothiazol-4-yl)-1H-imidazole-4-carboxamide, and
2,5-dibromo-N-(6-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)hexyl)-1-(2-morpholinothiazol-4-yl)-1H-imidazole-4-carboxamide.
6. A pharmaceutical composition, comprising:
an effective amount of the compound of claim 1 , and
a pharmaceutically acceptable carrier, additive and/or excipient.
7. The pharmaceutical composition of claim 6 , further comprising at least one additional anticancer agent.
8. A method for treating a disease state or condition in a patient wherein dysregulated protein activity is responsible for said disease or condition, said method comprising administering an effective amount of the compound according to claim 1 .
9. The compound according to claim 1 , wherein the AR binding moiety is the structure:
wherein Ring1 is:
Ring2 is:
and
R 101 is H.
10. The compound according to claim 1 , wherein the linker comprises a chemical structure represented by -A q -, in which q is an integer greater than 1, and A is independently selected from the group consisting of a bond, CR L1 R L2 , O, NR L3 , CONR L3 , and CO, wherein R L1 , R L2 , and R L3 , are each independently selected from the group consisting of H, halo, C 1-8 alkyl, OC 1-8 alkyl, NHC 1-8 alkyl, N(C 1-8 alkyl) 2 , C 3-11 cycloalkyl, OC 1-8 cycloalkyl, NHC 1-8 cycloalkyl, CONHC 1-8 alkyl, N(C 1-8 alkyl)CONH(C 1-8 alkyl), and NHCONH(C 1-8 alkyl).
11. The compound according to claim 10 , wherein the linker comprises a chemical structure represented by -A q -, in which q is an integer greater than 1, and A is independently selected from the group consisting of a bond, CR L1 R L2 , O, NR L3 and CONR L3 , wherein R L1 and R L2 , are each independently selected from the group consisting of H and C 1-8 alkyl, and wherein R L3 is H.
12. The compound according to claim 1 , wherein the E3LB moiety is a structure selected from E3LB-a, E3LB-b, E3LB-c and E3LB-d, wherein:
wherein “ ” in the above structures, represents a bond that may be stereospecific ((R) or (S)), or non-stereospecific;
R 1 is each independently selected from H, OH, CN, NH 2 , NR 2 R 3 , OCH 3 , OC 1-3 alkyl, CHF 2 , CH 2 F, CF 3 , halo, and C 1-6 alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more halo;
R 2 and R 3 are independently H, halo, C 1-6 alkyl wherein said alkyl is optionally substituted by 1 or more F, or taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms; and
R 4 is selected from the group consisting of H, and alkyl wherein said alkyl is linear or branched.
13. The compound according to claim 12 , wherein
R 1 is each independently selected from H, NH 2 , and halo; and
R 4 is H.
14. The compound according to claim 9 , wherein the E3LB moiety is a structure selected from E3LB-a, E3LB-b, E3LB-c and E3LB-d, wherein:
wherein “ ” in the above structures, represents a bond that may be stereospecific ((R) or (S)), or non-stereospecific;
R 1 is each independently selected from H, OH, CN, NH 2 , NR 2 R 3 , OCH 3 , OC 1-3 alkyl, CHF 2 , CH 2 F, CF 3 , halo, and C 1-6 alkyl wherein said alkyl is linear or branched and is optionally substituted by 1 or more halo;
R 2 and R 3 are independently H, halo, C 1-6 alkyl wherein said alkyl is optionally substituted by 1 or more F, or taken together with the atom they are attached to, form a 3-8 membered ring system containing 0-2 heteroatoms; and
R 4 is selected from the group consisting of H, and alkyl wherein said alkyl is linear or branched.
15. The compound according to claim 14 , wherein the linker comprises a chemical structure represented by -A q -, in which q is an integer greater than 1, and A is independently selected from the group consisting of a bond, CR L1 R L2 , O, NR L3 , CONR L3 , and CO, wherein R L1 , R L2 , and R L3 , are each independently selected from the group consisting of H, halo, C 1-8 alkyl, OC 1-8 alkyl, NHC 1-8 alkyl, N(C 1-8 alkyl) 2 , C 3-11 cycloalkyl, OC 1-8 cycloalkyl, NHC 1-8 cycloalkyl, CONHC 1-8 alkyl, N(C 1-8 alkyl)CONH(C 1-8 alkyl), and NHCONH(C 1-8 alkyl).
16. The compound according to claim 15 , wherein the linker comprises a chemical structure represented by -A q -, in which q is an integer greater than 1, and A is independently selected from the group consisting of a bond, CR L1 R L2 , O, NR L3 , and CONR L3 , wherein R L1 and R L2 , are each independently selected from the group consisting of H and C 1-8 alkyl, and wherein R L3 is H.
17. The compound according to claim 16 , wherein
R 1 is each independently selected from H, NH 2 , and halo; and
R 4 is H.
18. A pharmaceutical composition, comprising:
an effective amount of the compound of claim 16 , and
a pharmaceutically acceptable carrier, additive and/or excipient.
19. A pharmaceutical composition, comprising:
an effective amount of the compound of claim 17 , and
a pharmaceutically acceptable carrier, additive and/or excipient.